Common allergy spray tested as potential early COVID-19 treatment
NCT ID NCT06008860
Summary
This study is testing whether Astepro, a common allergy nasal spray, can help control early COVID-19 infection. Researchers will give the spray or a placebo to 280 vaccinated adults who just tested positive but have only mild or no symptoms. They will measure if the spray reduces the amount of virus in the body, eases symptoms, and lowers the chance of spreading COVID-19 to close contacts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.